Publications by authors named "D C Pevear"
β-Lactams are the most widely used antibiotics for the treatment of bacterial infections because of their proven track record of safety and efficacy. However, susceptibility to β-lactam antibiotics is continually eroded by resistance mechanisms. Emerging multidrug-resistant (MDR) strains possessing altered alleles (encoding PBP2) pose a global health emergency as they threaten the utility of ceftriaxone, the last remaining outpatient antibiotic.
View Article and Find Full Text PDFObjectives: Taniborbactam is a boronate-based β-lactamase inhibitor in clinical development in combination with cefepime.
Methods: Cefepime-taniborbactam and comparator broth microdilution MICs were determined for patient isolates of Enterobacterales (n = 20 725) and Pseudomonas aeruginosa (n = 7919) collected in 59 countries from 2018 to 2022. Taniborbactam was tested at a fixed concentration of 4 mg/L.
Article Synopsis
- Taniborbactam is a new β-lactamase inhibitor currently being tested in combination with cefepime to combat various drug-resistant bacterial infections, particularly from Pseudomonas aeruginosa.
- In clinical assessments involving thousands of bacterial isolates, the cefepime-taniborbactam combination significantly reduced the minimum inhibitory concentration (MIC) levels, demonstrating its effectiveness against multiple drug-resistant strains.
- Overall, cefepime-taniborbactam showed strong inhibitory activity, especially against strains resistant to other treatments, indicating its potential as a powerful option in tackling antibiotic resistance.
Article Synopsis
- - Ceftibuten-ledaborbactam etzadroxil is a novel oral medication being developed to treat complicated urinary tract infections caused by multidrug-resistant bacteria that produce certain β-lactamases, specifically in Ambler classes A, C, and D.
- - The medication works by converting the prodrug into an active form that inhibits β-lactamase enzymes, allowing it to effectively fight off resistant bacteria, including ESBL-positive and other non-susceptible strains.
- - In tests, ceftibuten-ledaborbactam showed strong efficacy, inhibiting a high percentage of various resistant clinical isolates, including 89.7% of MDR strains and over 91% of specific ES